Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383819
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2024-04-24
Brief Title:
Efficacy and Safety of Longidaza for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
Sponsor:
NPO Petrovax
Organization:
NPO Petrovax
Study Overview
Official Title:
Multicenter Randomized Double-blind Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza lyophilizate for preparation of solution for injection at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection
Detailed Description:
The main objective of the clinical study was to prove the superiority of the efficacy of the drug Longidaza over placebo when used in adult patients with residual changes in the lungs after COVID-19 infection based on the dynamics of respiratory function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None